MHC-I genotype and tumor mutational burden predict response to immunotherapy

BACKGROUND: Immune checkpoint blockade (ICB) with antibodies inhibiting cytotoxic T lymphocyte-associated protein-4 (CTLA-4) and programmed cell death protein-1 (PD-1) (or its ligand (PD-L1)) can stimulate immune responses against cancer and have revolutionized the treatment of tumors. The influence...

Descripción completa

Detalles Bibliográficos
Autores principales: Goodman, Aaron M., Castro, Andrea, Pyke, Rachel Marty, Okamura, Ryosuke, Kato, Shumei, Riviere, Paul, Frampton, Garrett, Sokol, Ethan, Zhang, Xinlian, Ball, Edward D., Carter, Hannah, Kurzrock, Razelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236948/
https://www.ncbi.nlm.nih.gov/pubmed/32430031
http://dx.doi.org/10.1186/s13073-020-00743-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236948/
https://www.ncbi.nlm.nih.gov/pubmed/32430031
http://dx.doi.org/10.1186/s13073-020-00743-4

Ejemplares similares